Literature DB >> 11722433

Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells.

J Ratajczak1, M Majka, J Kijowski, M Baj, Z K Pan, L A Marquez, A Janowska-Wieczorek, M Z Ratajczak.   

Abstract

The aim of this study was to identify signal transduction pathways activated by erythropoietin (EpO) and erythropoietin co-stimulatory factors (kit ligand), insulin-like growth factor, thrombopoietin, interleukin 3 and granulocyte-macrophage colony-stimulating factor) in normal human bone marrow CD34(+) cells and d 11 erythroid burst forming unit derived glycophorin+ cells. The activation of these signal transduction pathways was further correlated with various biological effects such as (i) cell proliferation, (ii) inhibition of apoptosis, (iii) activation of adhesion and (iv) secretion of the matrix metalloproteinases (MMPs) MMP-9 and MMP-2, and vascular endothelial growth factor (VEGF). We found that in human CD34(+) cells and erythroblasts erythropoietic factors may activate similar but different signalling pathways, and that activation of each of the JAK-STAT, MAPK p42/44 or PI-3K-AKT axes alone is not sufficient either to stimulate cell proliferation or inhibit apoptosis, suggesting that these processes are regulated by orchestrated activation of multiple signalling cascades. Accordingly, we found that although cell proliferation was more related to simultaneous activation of JAK-STAT and MAPK p42/44, the effect on cell survival correlated with activation of PI-3K-AKT, MAPK p42/44 and JAK-STAT proteins. We also demonstrated that differentiating normal human erythroid cells lose their adhesive properties and secrete angiopoietic factors such as MMP-9, MMP-2 and VEGF, and we postulate that this secretion by early erythroid cells may play a role in their maturation and egress from the haematopoietic niches of the bone marrow.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11722433     DOI: 10.1046/j.1365-2141.2001.03058.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.

Authors:  Oliver Bock; Johanne Neuse; Kais Hussein; Kai Brakensiek; Guntram Buesche; Thomas Buhr; Birgitt Wiese; Hans Kreipe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 2.  Emerging erythropoiesis-stimulating agents.

Authors:  Robert N Foley
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

3.  G-CSF and erythropoietin combination therapy for infarct repair: two plus two equals two? Editorial to: "Cytokine combination theray with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction" by F.S. Angeli et al.

Authors:  Carrie M Quinn; Buddhadeb Dawn
Journal:  Cardiovasc Drugs Ther       Date:  2010-12       Impact factor: 3.727

Review 4.  Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.

Authors:  Santosh K Sanganalmath; Ahmed Abdel-Latif; Roberto Bolli; Yu-Ting Xuan; Buddhadeb Dawn
Journal:  Basic Res Cardiol       Date:  2011-05-04       Impact factor: 17.165

5.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Authors:  Elizabeth O Hexner; Cynthia Serdikoff; Mahfuza Jan; Cezary R Swider; Candy Robinson; Shi Yang; Thelma Angeles; Stephen G Emerson; Martin Carroll; Bruce Ruggeri; Pawel Dobrzanski
Journal:  Blood       Date:  2007-11-05       Impact factor: 22.113

Review 6.  CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion.

Authors:  Magda Kucia; Kacper Jankowski; Ryan Reca; Marcin Wysoczynski; Laura Bandura; Daniel J Allendorf; Jin Zhang; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 7.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

8.  A novel protective effect of erythropoietin in the infarcted heart.

Authors:  Cyrus J Parsa; Akio Matsumoto; Jihee Kim; Ryan U Riel; Laura S Pascal; G Brant Walton; Richard B Thompson; Jason A Petrofski; Brian H Annex; Jonathan S Stamler; Walter J Koch
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  JAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogeny.

Authors:  Vladan P Cokic; Bhaskar Bhattacharya; Bojana B Beleslin-Cokic; Constance T Noguchi; Raj K Puri; Alan N Schechter
Journal:  J Transl Med       Date:  2012-06-07       Impact factor: 5.531

10.  A novel benzothiazole derivative YLT322 induces apoptosis via the mitochondrial apoptosis pathway in vitro with anti-tumor activity in solid malignancies.

Authors:  Song Xuejiao; Xia Yong; Wang Ningyu; Zhang Lidan; Shi Xuanhong; Xu Youzhi; Ye Tinghong; Shi Yaojie; Zhu Yongxia; Yu Luoting
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.